PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings. The company reported on Wednesday the FDA’s overall Clinical Evaluation Report (CER) drawing from the application is in its final stages with a “majority of requirements for submission [now] complete.” PainChek believes it will be in a position to provide a second update later this month. Its submission to the FDA ultimately acts, if approved, to allow PainChek to take its smartphone-based pain assessment and monitoring app into the aged care setting in …